TWP
BMRN icon

TFO Wealth Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

TFO Wealth Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4
Closed -$386 – 813
2023
Q4 		$386 Sell
4
-397
-99% -$35.1K ﹤0.01% 421
2023
Q3 		$34.8K Buy
401
+4
+1% +$356 0.01% 109
2023
Q2 		$34.4K Buy
+397
New +$37.4K 0.01% 100
2022
Q3 		– Sell
-7
Closed -$1K – 179
2022
Q2 		$1K Buy
+7
New +$557 ﹤0.01% 381

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TFO Wealth Partners's BMRN Position: Q1 2024 in Review

TFO Wealth Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 4 shares — an estimated $386 sold.

TFO Wealth Partners first reported a position in BMRN in Q2 2022 and held it in 4 quarters. The position peaked at $34.8K in Q3 2023. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • TFO Wealth Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • TFO Wealth Partners sold 4 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $386.
  • TFO Wealth Partners first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • TFO Wealth Partners's BioMarin Pharmaceuticals position peaked at $34.8K in Q3 2023.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on TFO Wealth Partners's 13F filing for Q1 2024, filed 14 May 2024.